0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Coagulation Factor VII Market Research Report 2026
Published Date: 2026-01-15
|
Report Code: QYRE-Auto-25N8769
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Human Coagulation Factor VII Market Outlook 2022
BUY CHAPTERS

Global Human Coagulation Factor VII Market Research Report 2026

Code: QYRE-Auto-25N8769
Report
2026-01-15
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Human Coagulation Factor VII Market Size

The global Human Coagulation Factor VII market was valued at US$ 1293 million in 2025 and is anticipated to reach US$ 1661 million by 2032, at a CAGR of 3.7% from 2026 to 2032.

Human Coagulation Factor VII Market

Human Coagulation Factor VII Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Human Coagulation Factor VII competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Human Coagulation Factor VII is a protein that plays a crucial role in the blood clotting process (hemostasis). It is one of the key components of the extrinsic pathway of the coagulation cascade, which is activated when tissue damage occurs. Factor VII works by binding to tissue factor (TF) exposed at the site of injury, forming a complex that activates other clotting factors (such as Factor X and Factor IX), ultimately leading to the formation of a blood clot.
In its recombinant form, Recombinant Human Coagulation Factor VIIa (rFVIIa) is used as a medication to help control bleeding, particularly in patients with hemophilia or other bleeding disorders who have developed inhibitors to conventional therapies.
Drivers of the Recombinant Human Coagulation Factor VII Market:
Rising Prevalence of Hemophilia and Bleeding Disorders: Recombinant Factor VIIa is primarily used in treating hemophilia, especially in patients with inhibitors to Factor VIII or IX. The growing global incidence of hemophilia and other bleeding disorders is a major driver of market demand.
Advancements in Recombinant Technology: Ongoing improvements in biotechnology have led to the development of safer and more effective recombinant coagulation products. These advancements reduce the risk of bloodborne pathogen transmission, increasing their adoption over plasma-derived alternatives.
Increased Use in Trauma and Surgery: Recombinant Factor VIIa is also used in managing severe bleeding during trauma and surgical procedures, further expanding its clinical applications and boosting demand, particularly in emergency care settings.
Rising Adoption in Off-Label Uses: While its primary indication is for hemophilia, rFVIIa is increasingly being used off-label to manage uncontrolled bleeding in non-hemophiliac patients, particularly in critical care and trauma settings. This broadens its potential market.
Favorable Reimbursement Policies in Developed Regions: In regions like North America and Europe, the availability of comprehensive insurance and reimbursement for advanced therapies like rFVIIa makes these treatments more accessible to patients, supporting market growth.
Challenges of the Recombinant Human Coagulation Factor VII Market:
High Cost of Treatment: Recombinant Factor VIIa therapy is expensive, which can limit access, especially in low-income countries and regions without robust healthcare funding or insurance coverage.
Potential for Off-Label Use Concerns: Despite its increasing use in off-label applications, concerns about the safety and efficacy of rFVIIa in non-hemophilia patients have led to caution in its broader application. Regulatory scrutiny on off-label use may impact market expansion.
Limited Awareness and Access in Developing Regions: In many developing countries, awareness of recombinant therapies for hemophilia is limited, and access to advanced treatments is constrained by inadequate healthcare infrastructure and funding.
Competition from Alternative Therapies: Emerging gene therapies, extended half-life clotting factors, and other innovative treatments for hemophilia may compete with or reduce the demand for rFVIIa in the future. These newer therapies promise more long-term efficacy or convenience.
Regulatory Challenges: The stringent regulatory approval process for biologics, along with the ongoing need for post-market surveillance, can slow down the introduction of new products or indications, impacting the pace of market growth.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.
This report delivers a comprehensive overview of the global Human Coagulation Factor VII market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Human Coagulation Factor VII. The Human Coagulation Factor VII market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Human Coagulation Factor VII market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Human Coagulation Factor VII manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Human Coagulation Factor VII Market Report

Report Metric Details
Report Name Human Coagulation Factor VII Market
Accounted market size in 2025 US$ 1293 million
Forecasted market size in 2032 US$ 1661 million
CAGR 3.7%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Prefilled Syringe
  • Vial
by Application
  • Congenital Hemophilia
  • Acquired Hemophilia
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company NovoNordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Human Coagulation Factor VII manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Human Coagulation Factor VII sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Human Coagulation Factor VII Market growing?

Ans: The Human Coagulation Factor VII Market witnessing a CAGR of 3.7% during the forecast period 2026-2032.

What is the Human Coagulation Factor VII Market size in 2032?

Ans: The Human Coagulation Factor VII Market size in 2032 will be US$ 1661 million.

What is the market share of major companies in Human Coagulation Factor VII Market?

Ans: The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%.

What is the Human Coagulation Factor VII Market share by region?

Ans: North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.

Who are the main players in the Human Coagulation Factor VII Market report?

Ans: The main players in the Human Coagulation Factor VII Market are NovoNordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM

What are the Application segmentation covered in the Human Coagulation Factor VII Market report?

Ans: The Applications covered in the Human Coagulation Factor VII Market report are Congenital Hemophilia, Acquired Hemophilia, Other

What are the Type segmentation covered in the Human Coagulation Factor VII Market report?

Ans: The Types covered in the Human Coagulation Factor VII Market report are Prefilled Syringe, Vial

1 Human Coagulation Factor VII Market Overview
1.1 Product Definition
1.2 Human Coagulation Factor VII by Type
1.2.1 Global Human Coagulation Factor VII Market Value by Type: 2025 vs 2032
1.2.2 Prefilled Syringe
1.2.3 Vial
1.3 Human Coagulation Factor VII by Application
1.3.1 Global Human Coagulation Factor VII Market Value by Application: 2025 vs 2032
1.3.2 Congenital Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Other
1.4 Global Human Coagulation Factor VII Market Size Estimates and Forecasts
1.4.1 Global Human Coagulation Factor VII Revenue 2021–2032
1.4.2 Global Human Coagulation Factor VII Sales 2021–2032
1.4.3 Global Human Coagulation Factor VII Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Human Coagulation Factor VII Market Competition by Manufacturers
2.1 Global Human Coagulation Factor VII Sales Market Share by Manufacturers (2021–2026)
2.2 Global Human Coagulation Factor VII Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Human Coagulation Factor VII Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Human Coagulation Factor VII, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Human Coagulation Factor VII, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Human Coagulation Factor VII, Product Types and Applications
2.7 Global Key Manufacturers of Human Coagulation Factor VII, Date of Entry into the Industry
2.8 Global Human Coagulation Factor VII Market Competitive Situation and Trends
2.8.1 Global Human Coagulation Factor VII Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Human Coagulation Factor VII Players Market Share by Revenue
2.8.3 Global Human Coagulation Factor VII Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Coagulation Factor VII Market Scenario by Region
3.1 Global Human Coagulation Factor VII Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Human Coagulation Factor VII Sales by Region: 2021–2032
3.2.1 Global Human Coagulation Factor VII Sales by Region: 2021–2026
3.2.2 Global Human Coagulation Factor VII Sales by Region: 2027–2032
3.3 Global Human Coagulation Factor VII Revenue by Region: 2021–2032
3.3.1 Global Human Coagulation Factor VII Revenue by Region: 2021–2026
3.3.2 Global Human Coagulation Factor VII Revenue by Region: 2027–2032
3.4 North America Human Coagulation Factor VII Market Facts & Figures by Country
3.4.1 North America Human Coagulation Factor VII Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Human Coagulation Factor VII Sales by Country (2021–2032)
3.4.3 North America Human Coagulation Factor VII Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Coagulation Factor VII Market Facts & Figures by Country
3.5.1 Europe Human Coagulation Factor VII Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Human Coagulation Factor VII Sales by Country (2021–2032)
3.5.3 Europe Human Coagulation Factor VII Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Coagulation Factor VII Market Facts & Figures by Region
3.6.1 Asia Pacific Human Coagulation Factor VII Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Human Coagulation Factor VII Sales by Region (2021–2032)
3.6.3 Asia Pacific Human Coagulation Factor VII Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Coagulation Factor VII Market Facts & Figures by Country
3.7.1 Latin America Human Coagulation Factor VII Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Human Coagulation Factor VII Sales by Country (2021–2032)
3.7.3 Latin America Human Coagulation Factor VII Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Coagulation Factor VII Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Coagulation Factor VII Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Human Coagulation Factor VII Sales by Country (2021–2032)
3.8.3 Middle East and Africa Human Coagulation Factor VII Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Coagulation Factor VII Sales by Type (2021–2032)
4.1.1 Global Human Coagulation Factor VII Sales by Type (2021–2026)
4.1.2 Global Human Coagulation Factor VII Sales by Type (2027–2032)
4.1.3 Global Human Coagulation Factor VII Sales Market Share by Type (2021–2032)
4.2 Global Human Coagulation Factor VII Revenue by Type (2021–2032)
4.2.1 Global Human Coagulation Factor VII Revenue by Type (2021–2026)
4.2.2 Global Human Coagulation Factor VII Revenue by Type (2027–2032)
4.2.3 Global Human Coagulation Factor VII Revenue Market Share by Type (2021–2032)
4.3 Global Human Coagulation Factor VII Price by Type (2021–2032)
5 Segment by Application
5.1 Global Human Coagulation Factor VII Sales by Application (2021–2032)
5.1.1 Global Human Coagulation Factor VII Sales by Application (2021–2026)
5.1.2 Global Human Coagulation Factor VII Sales by Application (2027–2032)
5.1.3 Global Human Coagulation Factor VII Sales Market Share by Application (2021–2032)
5.2 Global Human Coagulation Factor VII Revenue by Application (2021–2032)
5.2.1 Global Human Coagulation Factor VII Revenue by Application (2021–2026)
5.2.2 Global Human Coagulation Factor VII Revenue by Application (2027–2032)
5.2.3 Global Human Coagulation Factor VII Revenue Market Share by Application (2021–2032)
5.3 Global Human Coagulation Factor VII Price by Application (2021–2032)
6 Key Companies Profiled
6.1 NovoNordisk
6.1.1 NovoNordisk Company Information
6.1.2 NovoNordisk Description and Business Overview
6.1.3 NovoNordisk Human Coagulation Factor VII Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 NovoNordisk Human Coagulation Factor VII Product Portfolio
6.1.5 NovoNordisk Recent Developments/Updates
6.2 LFB SA HEMA Biologics
6.2.1 LFB SA HEMA Biologics Company Information
6.2.2 LFB SA HEMA Biologics Description and Business Overview
6.2.3 LFB SA HEMA Biologics Human Coagulation Factor VII Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 LFB SA HEMA Biologics Human Coagulation Factor VII Product Portfolio
6.2.5 LFB SA HEMA Biologics Recent Developments/Updates
6.3 AryoGen Pharmed
6.3.1 AryoGen Pharmed Company Information
6.3.2 AryoGen Pharmed Description and Business Overview
6.3.3 AryoGen Pharmed Human Coagulation Factor VII Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 AryoGen Pharmed Human Coagulation Factor VII Product Portfolio
6.3.5 AryoGen Pharmed Recent Developments/Updates
6.4 GENERIUM
6.4.1 GENERIUM Company Information
6.4.2 GENERIUM Description and Business Overview
6.4.3 GENERIUM Human Coagulation Factor VII Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 GENERIUM Human Coagulation Factor VII Product Portfolio
6.4.5 GENERIUM Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Coagulation Factor VII Industry Chain Analysis
7.2 Human Coagulation Factor VII Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Coagulation Factor VII Production Mode & Process Analysis
7.4 Human Coagulation Factor VII Sales and Marketing
7.4.1 Human Coagulation Factor VII Sales Channels
7.4.2 Human Coagulation Factor VII Distributors
7.5 Human Coagulation Factor VII Customer Analysis
8 Human Coagulation Factor VII Market Dynamics
8.1 Human Coagulation Factor VII Industry Trends
8.2 Human Coagulation Factor VII Market Drivers
8.3 Human Coagulation Factor VII Market Challenges
8.4 Human Coagulation Factor VII Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Human Coagulation Factor VII Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Human Coagulation Factor VII Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Human Coagulation Factor VII Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Human Coagulation Factor VII Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Human Coagulation Factor VII Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Human Coagulation Factor VII Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Human Coagulation Factor VII Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Human Coagulation Factor VII Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Human Coagulation Factor VII, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Human Coagulation Factor VII, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Human Coagulation Factor VII, Product Types and Applications
 Table 12. Global Key Manufacturers of Human Coagulation Factor VII, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Coagulation Factor VII Companies by Tier (Tier 1, Tier 2, Tier 3), based on Human Coagulation Factor VII Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Coagulation Factor VII Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Human Coagulation Factor VII Sales by Region (K Units), 2021–2026
 Table 18. Global Human Coagulation Factor VII Sales Market Share by Region (2021–2026)
 Table 19. Global Human Coagulation Factor VII Sales by Region (K Units), 2027–2032
 Table 20. Global Human Coagulation Factor VII Sales Market Share by Region (2027–2032)
 Table 21. Global Human Coagulation Factor VII Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Human Coagulation Factor VII Revenue Market Share by Region (2021–2026)
 Table 23. Global Human Coagulation Factor VII Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Human Coagulation Factor VII Revenue Market Share by Region (2027–2032)
 Table 25. North America Human Coagulation Factor VII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Human Coagulation Factor VII Sales by Country (K Units), 2021–2026
 Table 27. North America Human Coagulation Factor VII Sales by Country (K Units), 2027–2032
 Table 28. North America Human Coagulation Factor VII Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Human Coagulation Factor VII Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Human Coagulation Factor VII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Human Coagulation Factor VII Sales by Country (K Units), 2021–2026
 Table 32. Europe Human Coagulation Factor VII Sales by Country (K Units), 2027–2032
 Table 33. Europe Human Coagulation Factor VII Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Human Coagulation Factor VII Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Human Coagulation Factor VII Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Human Coagulation Factor VII Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Human Coagulation Factor VII Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Human Coagulation Factor VII Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Human Coagulation Factor VII Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Human Coagulation Factor VII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Human Coagulation Factor VII Sales by Country (K Units), 2021–2026
 Table 42. Latin America Human Coagulation Factor VII Sales by Country (K Units), 2027–2032
 Table 43. Latin America Human Coagulation Factor VII Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Human Coagulation Factor VII Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Human Coagulation Factor VII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Human Coagulation Factor VII Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Human Coagulation Factor VII Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Human Coagulation Factor VII Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Human Coagulation Factor VII Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Human Coagulation Factor VII Sales (K Units) by Type (2021–2026)
 Table 51. Global Human Coagulation Factor VII Sales (K Units) by Type (2027–2032)
 Table 52. Global Human Coagulation Factor VII Sales Market Share by Type (2021–2026)
 Table 53. Global Human Coagulation Factor VII Sales Market Share by Type (2027–2032)
 Table 54. Global Human Coagulation Factor VII Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Human Coagulation Factor VII Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Human Coagulation Factor VII Revenue Market Share by Type (2021–2026)
 Table 57. Global Human Coagulation Factor VII Revenue Market Share by Type (2027–2032)
 Table 58. Global Human Coagulation Factor VII Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Human Coagulation Factor VII Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Human Coagulation Factor VII Sales (K Units) by Application (2021–2026)
 Table 61. Global Human Coagulation Factor VII Sales (K Units) by Application (2027–2032)
 Table 62. Global Human Coagulation Factor VII Sales Market Share by Application (2021–2026)
 Table 63. Global Human Coagulation Factor VII Sales Market Share by Application (2027–2032)
 Table 64. Global Human Coagulation Factor VII Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Human Coagulation Factor VII Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Human Coagulation Factor VII Revenue Market Share by Application (2021–2026)
 Table 67. Global Human Coagulation Factor VII Revenue Market Share by Application (2027–2032)
 Table 68. Global Human Coagulation Factor VII Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Human Coagulation Factor VII Price (US$/Unit) by Application (2027–2032)
 Table 70. NovoNordisk Company Information
 Table 71. NovoNordisk Description and Business Overview
 Table 72. NovoNordisk Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. NovoNordisk Human Coagulation Factor VII Product
 Table 74. NovoNordisk Recent Developments/Updates
 Table 75. LFB SA HEMA Biologics Company Information
 Table 76. LFB SA HEMA Biologics Description and Business Overview
 Table 77. LFB SA HEMA Biologics Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. LFB SA HEMA Biologics Human Coagulation Factor VII Product
 Table 79. LFB SA HEMA Biologics Recent Developments/Updates
 Table 80. AryoGen Pharmed Company Information
 Table 81. AryoGen Pharmed Description and Business Overview
 Table 82. AryoGen Pharmed Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. AryoGen Pharmed Human Coagulation Factor VII Product
 Table 84. AryoGen Pharmed Recent Developments/Updates
 Table 85. GENERIUM Company Information
 Table 86. GENERIUM Description and Business Overview
 Table 87. GENERIUM Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. GENERIUM Human Coagulation Factor VII Product
 Table 89. GENERIUM Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Human Coagulation Factor VII Distributors List
 Table 93. Human Coagulation Factor VII Customers List
 Table 94. Human Coagulation Factor VII Market Trends
 Table 95. Human Coagulation Factor VII Market Drivers
 Table 96. Human Coagulation Factor VII Market Challenges
 Table 97. Human Coagulation Factor VII Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Coagulation Factor VII
 Figure 2. Global Human Coagulation Factor VII Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Human Coagulation Factor VII Market Share by Type: 2025 & 2032
 Figure 4. Prefilled Syringe Product Picture
 Figure 5. Vial Product Picture
 Figure 6. Global Human Coagulation Factor VII Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Human Coagulation Factor VII Market Share by Application: 2025 & 2032
 Figure 8. Congenital Hemophilia
 Figure 9. Acquired Hemophilia
 Figure 10. Other
 Figure 11. Global Human Coagulation Factor VII Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Human Coagulation Factor VII Market Size (US$ Million), 2021–2032
 Figure 13. Global Human Coagulation Factor VII Sales (K Units), 2021–2032
 Figure 14. Global Human Coagulation Factor VII Average Price (US$/Unit), 2021–2032
 Figure 15. Human Coagulation Factor VII Report Years Considered
 Figure 16. Human Coagulation Factor VII Sales Share by Manufacturers in 2025
 Figure 17. Global Human Coagulation Factor VII Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Human Coagulation Factor VII Players: Market Share by Revenue in Human Coagulation Factor VII in 2025
 Figure 19. Human Coagulation Factor VII Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Human Coagulation Factor VII Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Human Coagulation Factor VII Sales Market Share by Country (2021–2032)
 Figure 22. North America Human Coagulation Factor VII Revenue Market Share by Country (2021–2032)
 Figure 23. U.S. Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Human Coagulation Factor VII Sales Market Share by Country (2021–2032)
 Figure 26. Europe Human Coagulation Factor VII Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Human Coagulation Factor VII Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Human Coagulation Factor VII Revenue Market Share by Region (2021–2032)
 Figure 34. China Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Taiwan Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Indonesia Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Thailand Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Malaysia Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Philippines Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Latin America Human Coagulation Factor VII Sales Market Share by Country (2021–2032)
 Figure 45. Latin America Human Coagulation Factor VII Revenue Market Share by Country (2021–2032)
 Figure 46. Mexico Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Brazil Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Argentina Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Middle East and Africa Human Coagulation Factor VII Sales Market Share by Country (2021–2032)
 Figure 50. Middle East and Africa Human Coagulation Factor VII Revenue Market Share by Country (2021–2032)
 Figure 51. Turkey Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Saudi Arabia Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. U.A.E Human Coagulation Factor VII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Global Sales Market Share of Human Coagulation Factor VII by Type (2021–2032)
 Figure 55. Global Revenue Market Share of Human Coagulation Factor VII by Type (2021–2032)
 Figure 56. Global Human Coagulation Factor VII Price (US$/Unit) by Type (2021–2032)
 Figure 57. Global Sales Market Share of Human Coagulation Factor VII by Application (2021–2032)
 Figure 58. Global Revenue Market Share of Human Coagulation Factor VII by Application (2021–2032)
 Figure 59. Global Human Coagulation Factor VII Price (US$/Unit) by Application (2021–2032)
 Figure 60. Human Coagulation Factor VII Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS